



Novartis India Limited
Registered Office:
Inspire BKC
Part of 601 & 701
Bandra Kurla Complex
Bandra (East)
Mumbai – 400 051
Maharashtra, India
Tel +91 22 50243000
Fax +91 22 50243010
Email: india.investors@novartis.com
CIN No. L24200MH1947PLC006104
Website: www.novartis.in

December 2, 2020

The Secretary
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001

Sub.: Disclosure of related party transactions for the half year ended on September 30, 2020

Ref.: 1. Regulation 23(9) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”)
2. Scrip Code: 500672

Dear Sir/ Madam,

Apropos the subject matter quoted above, please find enclosed herewith the disclosure of Related Party Transactions on a standalone basis, in format as specified in the relevant accounting standards for the half year ended on September 30, 2020.

The above is for your information and the same is also available on the Company's website i.e. www.novartis.in

Thanking you

Yours sincerely,

For **Novartis India Limited**

Trivikram Guda
Company Secretary &
Compliance Officer

Novartis India Limited
Related Party Disclosures for the period - Half year ended on September 30, 2020

(A) Enterprise where control exists

Holding Company and Ultimate Holding Company Novartis AG, Basel, Switzerland

(B) Other Related Parties with whom the company had transactions during the year and/or the previous year

(i) Fellow Subsidiaries

Novartis Pharma Services INC Kenya
Novartis Healthcare Private Limited, India
Novartis Holding AG, Switzerland
Novartis Pharma AG, Switzerland
Sandoz Private Limited, India

(ii) List of other related parties (Post-employment benefit plan of Novartis India Limited)

Novartis India Limited Employees' Provident Fund

(C) Key Management Personnel

Mr. Trivikram Guda - Company Secretary & Compliance Officer
Mr. Sanjay Murdeshwar - Managing Director
Mr. Felix Doss - Chief Financial Officer

Mr. Sanker Parameswaran – Independent Director
Mr. Jai Hiremath - Independent Director
Ms. Sandra. Martyes - Independent Director
Mr. Christopher Snook - Director (Chairman)
Ms. Monaz Noble - Director

(D) Disclosure of transactions between the company and related parties and outstanding balances as at the year end:

	30th Sept 2020
	in ₹ million
(a) Holding Company and Ultimate Holding Company	
Dividend paid	174.5
Royalty Expense	12.8
Balance as at the year end - Outstanding Payable	51.7
(b) Fellow Subsidiaries	
	30th Sept 2020
	in ₹ million
Purchases of Stock-in-Trade	
Novartis Pharma AG	405.5
	405.5
Sale of Services	
Sandoz Private Limited	9.9
	9.9
Commission Income	
Novartis Healthcare Private Limited	90.5
	90.5
Services Availed	
Novartis Healthcare Private Limited	15.4
Novartis Pharma AG	1.1
	16.5
Expenses paid by related party on behalf of the Company	
Novartis Pharma Services INC Kenya	18.7
	18.7
	30th Sept 2020
	in ₹ million
Balances as at the year end -	
Outstanding Receivables	
Novartis Healthcare Private Limited	54.6
Novartis Pharma AG	468.2
Sandoz Private Limited	7.4
Novartis Pharma Services INC Kenya	2.2
	532.3
	30th Sept 2020
	in ₹ million
Outstanding Payables	
Novartis Healthcare Private Limited	727.5
Novartis Holding AG	(0.6)
Novartis Pharma AG	93.5
	820.5
(c) Post Employment Benefit Plans of Novartis India Limited	
	30th Sept 2020
	in ₹ million
Contribution to In-house Trust for Post Employment Benefits	
Novartis India Limited Employees' Provident Fund	21.9
	21.9
(d) Key Management Personnel Compensation	
	30th Sept 2020
	in ₹ million
Commission to Independent Directors	1.5
Sitting fees to Independent Directors	0.5
Total compensation	2.0

Notes:

1) Outstanding balances at the half year-end are unsecured and interest free and settlement occurs in cash.